Future of promising Alzheimer’s treatment Leqembi could depend on access to data reporting, analysis:...
By
Aaron Dorman
Feb 16, 2024
Organizations must have clearer guidelines as to how data on lecanemab will be collected, pooled and studied, policy experts say.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...
COVID-19 meds like Paxlovid will soon have big price tags
Oct 30, 2023
The pills still will be available at no cost until those bought earlier by the federal government run out.
CMS announces Alzheimer’s drug coverage policy, but ‘the devil is in the details,’ experts say
By
Kimberly Bonvissuto
Jun 01, 2023
A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in...
Inconsistent state regulations, staff training produce wide variations among states’ antipsychotic...
By
Kimberly Bonvissuto
Feb 28, 2023
Researchers are calling for a closer look at the use of antipsychotics among assisted living residents with dementia after a study found wide variations in prescribing patterns.
Feds’ antipsychotic drug reduction efforts in assisted living fail to produce success seen in nursing...
By
Alicia Lasek
Aug 23, 2022
A federal initiative to reduce antipsychotic prescribing in long-term care facilities failed to impact prescriptions in assisted living residents with dementia, the first study of its kind has found.